The United States cell therapy market size is projected to exhibit a growth rate (CAGR) of 11.60% during 2024-2032. The rising number of chronic ailments, such as cancer, diabetes, and cardiovascular diseases, the increasing investment in cell therapy research and development (R&D) in private and public sectors, and several advancements in biotechnology are essential in the expansion of cell therapy, represent some of the key factors driving the market.
 
					Mackinnon Ritchie
 
					Stilling Dugan
 
					Potts Henson
 
					Hartman Dahlgaard
 
					Mcguire Pridgen
 
					Korsholm Ballard
 
					Sander Jonsson
 
					Frost Valencia
 
					Cullen Marcher
 
					Rush Bernard